FORT WORTH, Texas — Although gout is well known for imitating several other conditions, clinicians should exercise caution to eliminate septic arthritis as a potential diagnosis, as delay in treatment ...

Malik, Schumacher, Dinnella, and Clayburne compared the sensitivity and specificity of the above criteria with synovial-fluid analysis. 18 Results showed the following predictive values: Rome, 76.9%; ...

Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid Two pivotal Phase III studies showed ACZ885 may meet ...

People in Europe who suffer from frequent attacks of acute gouty arthritis and who either do not respond to currently available drugs or are unable to tolerate them may soon have access to another ...

Novartis announced results of two Phase 3 studies of ACZ885 (canakinumab) for the treatment of severe gouty arthritis. These randomized, multicenter, double-blind, double-dummy, active-controlled ...

In a recent study published in the BMC Musculoskeletal Disorders, researchers performed a systematic review and meta-analysis to explore the effects of nanoparticles on gouty arthritis using animal ...

Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments Ilaris® is the first biologic approved in the EU for ...

Aim: It has been a popular belief that gout does not typically occur in patients with rheumatoid arthritis (RA). Our aim was to assess the occurrence, prevalence, clinical presentation and possible ...

Gout sounds like a disease that shouldn’t exist anymore, especially since it’s referred to as the “disease of kings” because of its connection to royal leaders like Henry VIII, who lived with the ...

IN the course of three recent consecutive weekly meetings of the King County Hospital Arthritis Clinic 2 Filipino males appeared, both of whom were suffering from acute gouty arthritis. The low number ...

Probenecid (Benemid) is a uricosuric agent that inhibits the reabsorption of uric acid in proximal tubules of the kidney. 36 Pharmacologic therapy typically begins at 500 mg b.i.d. and gradually ...